In this phase I, first-in-human phase I study, PF-07062119 monotherapy demonstrated a generally tolerable safety profile within the context of this early-phase study with evidence of clinical activity in patients with advanced/metastatic GI cancers.
M. Fakih, Toshihiko Doi, A. Tolcher et al.· Cancer Research Communicatio...· 0 citations
Molecular residual disease (MRD), detected via circulating tumor DNA (ctDNA) after curative-intent surgery, identifies resectable solid tumor patients at high recurrence risk, thereby enabling enriched trials with larger effect sizes and smaller samples. Yet enrichment narrows the eligible population and thus challenge...
S. Kobayashi, T. Hashimoto, H. Bando et al.· Cancer Cell· 0 citations
Advances in cell-free DNA (cfDNA) processing and error-suppressed next-generation sequencing (NGS) have enabled detection of circulating tumor DNA (ctDNA) at low abundance for assessment of minimal residual disease (MRD). MRD testing requires high analytical specificity near the stochastic limit of rare-molecule sampli...
M. Clark, R. Prathapam, K. Bramlett et al.· Journal of Molecular Diagnos...· 0 citations
ARCAD-derived SCAs reliably reproduced control-arm OS and benchmark treatment-effect estimates from landmark RCTs in mCRC, and supports benchmarking, trial design, and exploratory analyses when conventional control arms are impractical.
M. Raeisi, T. André, Q. Shi et al.· Journal of the National Canc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.